arly growth response (Egr)-1, 1 also known as NGFI-A, 2 zif268, 3 krox-24, 4 and TIS8 5 , is a transcription factor and product of an immediate-early gene located on human chromosome 5q23-q31 encoding 2 exons. 1 The DNA binding domain of Egr-1 contains 3 zinc fingers of the Cys 2 -His 2 subtype that bind preferentially to GC-rich elements. 6 Egr-1 is poorly expressed in the normal artery wall but is activated by acute mechanical injury 7 and other vascular stresses such as angiotensin II, 8 lysophosphatidylcholine, 9 PDGF, 10 FGF-1, 11 FGF-2, 12 and fluid shear stress. 13 Transcription of the Egr-1 gene is dependent on Ras-Raf-MEK-ERK1/2 pathway signaling (which is itself activated by acute vascular injury 8, 12, 14, 15 ) and serum-response elements in the Egr-1 promoter. 16 These elements mediate Egr-1 inducibility in response to a variety of agonists, including thrombin, 17 lipopolysaccharide, 18 and hypoxia, 19 and, as in the c-Fos promoter, involve interactions between ternary complex factors (TCF) and serum response factor (SRF). 20 Recent studies suggest that nuclear accumulation of Egr-1 appears to require interaction of Gab1 (growth factor receptor-bound protein 2 [Grb2]-associated binder-1) with ERK1/2 via the proline-rich METbinding domain in Gab1. 21 Egr-1 is a master regulator because it controls the expression of a wide variety of genes. Oligonucleotide-based microarray analysis provided insights into the spectrum of these Egr-1-dependent genes. Expression of more than 300 genes was altered (229 upregulated, 74 downregulated) 3-fold or more 48 hours following human umbilical vein endothelial cell (HUVEC) infection with an adenovirus-driven form of Egr-1 resistant to transcriptional repression by its endogenous inhibitor NAB. 22 These genes may broadly be grouped as transcription factors (eg, Egr-1, NAB1), signaling factors (eg, Notch3, Rad), growth factors and cytokines (eg, TGF-␤, CLF1), cell-cycle regulators (eg, cyclin D1, p57 kip2 , matrix proteins [eg, fibronectin, osteopontin]) and ion channel regulators (eg, Na ϩ /Ca 2ϩ -exchanger). 22 Egr-1-dependent gene expression involves functional cooperativity (positive and negative) between Egr-1 and a growing number of other transcription or regulatory factors including nuclear factor of activated T cells (NFAT), 23, 24 steroidogenic factor-1 (SF-1), 25, 26 AP-2 and the glucocorticoid receptor, 27 p300, 25 RelA (p65), 28, 29 p53, 30 Sp1 31 as well as NAB (NAB1 32 and NAB2 33 ). It is therefore quite likely that Egr-1 does not act alone, but works in concert with other transcription factors. We described functional interplay between Egr-1 and Sp1 in the context of PDGF-A 34 and PDGF-B 7 promoters, now recognized as a more general regulatory circuit in inducible gene expression. Examples of other genes that may be controlled by Egr-1/Sp1 exchange include the HGF receptor, 35 manganese superoxide dismutase, 36 RET protooncogene, 37 tissue factor, 38 and 5-lipoxogenase. 39 This article reviews the growing evidence implicating Egr-1 in the control of a wide variety of cardiovascular pathological processes (Figure) .
Atherosclerosis
Egr-1 contributes to the pathogenesis of atherosclerotic lesions. McCaffrey et al performed cDNA array and RT-PCR analysis comparing tissue from the dissected fibrous cap of human lesions with the underlying tunica media of patients with obstructive carotid atherosclerosis and revealed 5-fold higher levels of Egr-1 in lesions. 40 Egr-1 was expressed mainly in ␣-SM-actin-positive cells in areas of macrophage infiltration, as well as in endothelial cells. 40 Subsequent studies comparing Egr-1 protein expression in cells derived from the human atherosclerotic lesion and media at low passage revealed greater expression in lesions. 41 Egr-1 is expressed in SMCs of atherosclerotic lesions in LDL receptor-deficient mice fed a high-fat diet for 5 weeks. Egr-1 staining intensity in lesions increased progressively by 10 and 20 weeks, 40 observations supported by studies in apolipoprotein E (apoE)-null mice. 42 Lesion area in mice deficient in both Egr-1 and apoE is dramatically reduced compared with mice lacking apoE alone. Female 24-week-old double-knockout mice fed a normal chow diet had 7-fold smaller lesions than apoE-null mice. 42 Egr-1 is also found in inflammatory cells of vascular lesions. For example, Egr-1 is expressed in CD68 ϩ macrophages of aortic atherosclerotic lesions in fructose-fed LDL receptor-deficient mice. 43 In innominate arteries of apoE Ϫ/Ϫ mice, Egr-1 was primarily colocalized with macrophages in the lateral margins of advanced atherosclerotic lesions. 44 Thus Egr-1 is found in several cell types within atherosclerotic lesions and is a factor required in atherogenesis. Egr-1 may also play a role in the pathophysiology of stenosed calcific valvular disease. Egr-1 has been detected in calcific human aortic valve cusps compared with noncalcified normal cusps. 45 Egr-1 expression in lesions can be reduced with standard pharmacological agents. For example, simvastatin (50 mg/kg/d), a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, inhibits Egr-1 protein expression in lesions of apoE-null mice by more than 60%. 44 This was accompanied by reduced tissue factor expression and fewer macrophages in the lesion. 44 Chlamydia pneumoniae, a bacterium implicated in atherogenesis, can induce Egr-1 mRNA and protein expression in SMCs and macrophages within 1 hour apparently via ERK signaling. 46 ,47 siRNA targeting human EGR-1 blocks C pneumoniae inducible DNA synthesis after 48 hours. 46 
Intimal Thickening After Acute Vascular Injury
Almost a decade ago we demonstrated by in situ hybridization that Egr-1 is rapidly (within hours) and transiently induced at the endothelial wound edge following balloon catheter scrape injury to the aortae of rats. 7 In the same (endothelial denudation) model, we found that Egr-1 is expressed later by migrating SMCs. 10 The expression and nuclear translocation of Egr-1 after mechanical injury is, at least in vitro, dependent on the release of endogenous FGF-2 and its paracrine activation of MEK/ERK-dependent signaling. 12 FGF-2, a potent agonist of Egr-1, plays an important role vascular repair after injury. FGF-2 is locally and transiently (within minutes) released in the coronary arteries of humans undergoing stenting. 48 SMC migration in rats after deendothelialization is augmented by systemic administration of FGF-2 and blocked by infusion of neutralizing antibodies to FGF-2. 49 That Egr-1 plays a critical role as a mediator of SMC growth and intimal thickening in the reparative response to vascular injury has been demonstrated using a variety of synthetic nucleic acid-based gene-silencing approaches. For example, antisense oligonucleotides (15-mers) with phosphorothioate linkages targeting various regions in rat Egr-1 mRNA, unlike random, scrambled, sense or mismatch versions, blocked primary aortic SMC replication and regrowth after in vitro scraping injury. 50 Catalytic 34-mer DNA molecules (DNAzyme ED5) which target and degrade rat Egr-1 mRNA, also inhibited SMC growth and repair in vitro and, when delivered adventitially to rat common carotid arteries, suppressed Egr-1 protein expression after 1 hour and intimal thickening 14 days after balloon angioplasty. 51 ED5 also blocks neointima formation in rat carotid arteries 18 days after permanent ligation. 52 The DNAzyme has since been used to suppress the development of other proliferative states. For example, ED5 reduces cortical Egr-1 mRNA expression and interstitial fibrosis in rats 7 days after renal obstruction (unilateral ureteral ligation) and delivery by electroporation. In this model, the DNAzyme inhibited TGF-␤, ␣-SM-actin and type I collagen mRNA expression. 53 DNAzymes targeting the human version of Egr-1, which also inhibit Egr-1 expression and proliferation of human and porcine aortic SMCs, reduce in-stent restenosis in pig coronary arteries 30 days after endoluminal delivery at the time of stenting. 54 We have recently reported that the inhibitory potency of DNAzymes in SMCs can be improved by the incorporation of certain structural modifications such as locked nucleic acids (LNA). 55 Ohtani et al demonstrated that intraluminal delivery of double-stranded cis-element oligonucleotide "decoys" bearing Egr-1 binding sites inhibit the expression of Egr-1-dependent genes, such as PDGF-B, TGF-␤, and MCP-1, and block intimal hyperplasia 7 and 28 days, respectively, after balloon injury to the carotid arteries of hypercholesterolemic rabbits. 56 It is presently unknown whether injury-inducible intimal thickening is compromised in Egr-1-null mice. Thus, antisense, DNAzyme and decoy approaches targeting Egr-1, which is rapidly upregulated by acute injury, may be useful as antigene strategies in vascular occlusive disorders. Blockade of neointima formation by Schematic depicting various cardiovascular pathological processes thought to be under transcriptional control of the inducible immediate-early gene product and zinc finger nuclear regulatory factor, Egr-1. Egr-1 is activated by multiple pathophysiological stimuli involving mitogen-activated protein kinases and SRE-dependent transcription. Egr-1, once induced, as a master regulator, controls effector genes implicated in a myriad of cardiovascular conditions such as lesion development, hypertrophy, ischemia, and angiogenesis. Egr-1 is but 1 of many transcription factors involved in these processes and its interactions with these other factors are yet to be delineated.
targeting other transcription factors, such as NFAT, 57 STAT3, 58 nuclear factor B, 59 and c-Jun, 60 that are also activated by arterial injury 57, 58, 60, 61 suggests that the possibility of compound inhibition of postangioplasty restenosis in strategies targeting multiple factors.
Hypoxia and Ischemia
Understanding transcriptional changes in the brain after ischemia may provide therapeutic molecular targets for the treatment of stroke, a consequence of atherosclerosis. Several lines of evidence identify Egr-1 as a hypoxia-inducible factor. Gubits et al showed that unilateral ligation of the common carotid artery in 7-day-old pup rats followed by 3 hours of hypoxia (8% O 2 ) results in increased Egr-1 mRNA expression in the ipsilateral forebrain within a few hours. 62 DNA microarray studies later demonstrated that Egr-1 is upregulated in the hippocampal CA1 sector in rats 2 minutes after global cerebral ischemia. 63 Finally, Egr-1 and Egr-1-dependent genes (such as PAI-1, ICAM-1, IL-1␤, and MIP-1) are induced in the periinfarction cortex of adult rats 24 hours after permanent middle cerebral artery occlusion. 64 Egr-1 is also upregulated in the kidney in response to renal artery occlusion. 65, 66 Egr-1 appears to be involved in the pathogenesis of ischemic lung tissue damage. In a mouse model of lung ischemia and ischemia-reperfusion, Egr-1 (but not Sp1) was induced 3-fold within 15 minutes and approximately 10-fold after 1 hour, then induced 20-fold after 3 hours of reperfusion. 67 That Egr-1-deficient mice display increased survival and lung function after pulmonary ischemia-reperfusion demonstrates a causal relationship between Egr-1 and ischemiareperfusion damage. 67 Egr-1-deficient animals had lower expression of genes such as tissue factor, PAI-1, and ICAM-1, suggesting Egr-1 governance of procoagulant and proinflammatory genes during ischemia-reperfusion injury. Recent studies show that Egr-1 expression, ERK, and JNK phosphorylation after lung ischemia-reperfusion is reduced in PKC-␤ knockout mice or wild-type mice fed the PKC-␤ inhibitor ruboxistaurin, 68 demonstrating the importance of this PKC isoform in Egr-1 signaling. Hypoxia induces Egr-1 expression in endothelial cells via the PKC-␣-mediated Ras/Raf-1/ERK1/2 pathway. 69 cDNA array analysis further showed that Egr-1 mRNA levels in rat lungs increase 5-fold 1 hour after warm ischemia following surgical extirpation compared with controls. 70 Chronic exposure (14 days) of newborn calves to 12%, rather than 21%, O 2 upregulates Egr-1 protein expression in pulmonary artery adventitial fibroblasts. Hypoxia (1%) induces Egr-1 expression and DNA synthesis in fibroblasts cultured from hypoxic animals, after 6 and 24 hours, respectively. Hypoxia-inducible fibroblast proliferation, cyclin D, and epidermal growth factor receptor expression is inhibited after 48 hours. 71 Interestingly, Egr-1 mRNA is increased 2-fold in the lung and 6-fold in the rat heart 6 hours following exposure to 0.1% carbon monoxide. 72 Egr-1 is activated in response to cardiac ischemia. For example, Egr-1 mRNA is expressed after cardioplegic arrest and reperfusion in human hearts and in rat hearts subjected to cold cardioplegia for 40 minutes followed by 40 minutes of reperfusion. 73 Egr-1 expression is thus regulated by ischemic and ischemic-reperfusive stress in multiple cell and tissue types.
Cardiac Hypertrophy
A role for Egr-1 in cardiac hypertrophy was suggested by the capacity of norepinephrine and phenylephrine to stimulate Egr-1 in rat hearts. 74 Recently, Buitrago et al 75 demonstrated that NAB1 and Egr-1 serve as endogenous regulators of pathologic cardiac hypertrophy. Left ventricular myocardial NAB1 expression increased in ␤ 1 -adrenergic receptor transgenic mice, a well-established model of heart failure. Adenovirus-driven NAB1 suppressed cardiomyocyte hypertrophy, skeletal organization, and protein synthesis, whereas cardiomyocyte growth was unaffected by a mutant form of NAB1 that lacked the Egr-binding site. Although adrenergic stimulation led to ventricular hypertrophy in wild-type mice, this was significantly reduced in NAB1-overexpressing mice. Complementing these observations, ventricular and cardiomyocyte hypertrophy were reduced in Egr-1-null mice subjected to transverse aortic constriction-induced pressure overload. In contrast, physiologic hypertrophy induced by exercise was unaffected in NAB1 transgenic mice compared with wild-type animals, suggesting a role in pathological but not physiological hypertrophy. 75 Saadane et al by contrast showed no change in total ventricular weight in Egr-1-deficient mice after chronic infusion of isoproterenol/phenylephrine compared with wild type mice, despite dramatic differences in adrenoreceptor-stimulated expression of genes such as GATA-4 and Nkx2.5. 76
Allograft Rejection
Egr-1 also appears to play a role in cardiac allograft rejection. Egr-1 mRNA and protein were detected in leukocytes and cardiac myocytes of grade 3 endomyocardial biopsies but not in grade 0 biopsies. Egr-1 is expressed in the coronaries of patients with coronary artery vasculopathy (CAV). 77 These findings are supported by observations of Egr-1 expression in SMCs of rejected cardiac allografts in monkeys undergoing heterotopic abdominal heart transplants. 78 Egr-1 and Egr-1-dependent genes, such as ICAM-1, VCAM-1, and PDGF-A, are induced following transplantation of heterotopic murine cardiac allografts. In contrast, these genes are poorly expressed in homozygous Egr-1-deficient donor allografts, in which parenchymal rejection and CAV are suppressed. 79 Antisense Egr-1 oligonucleotides delivered at the time of organ harvest inhibit Egr-1 expression and the development of CAV. 79 Antisense Egr-1 also block lung transplant leukostasis, inflammation, and thrombosis in rats together with improved graft function and recipient survival. 80 These findings thus implicate Egr-1 in vasculopathy and organ rejection.
Angiogenesis
Inducible expression of Egr-1 in activated vascular endothelium 7 led us to investigate whether Egr-1 may play direct a role in the angiogenic process. Observations of poor neovascularization in subcutaneous Matrigel implants of Egr-1-deficient mice were consistent with suppressed implant angiogenesis in normal mice using Egr-1 DNAzymes. These agents inhibited microvascular endothelial cell proliferation and migration and microtubule network formation in vitro, blocked VEGF-inducible corneal neovascularization in rats, and reduced tumor growth and tumor angiogenesis in mice. 81 These findings are complemented by investigations using NAB2. NAB2, but not a dominant-negative form, abrogates tubule formation in culture. 82 Additionally, adenovirus-driven NAB2 reduces in vitro tubule and sprout formation and decreases plug neovascularization in mice. 83 How Egr-1 controls angiogenesis is presently unclear, but is likely to involve its orchestration of multiple growth mediators and receptors. For example, Egr-1 controls the expression of FGF-2, 81 Flt-1, 84 tissue factor, 83 and uPA 83 in the context of angiogenesis. Recent studies indicate that Egr-1 controls CCN1, an angiogenic factor produced by SMCs that promotes cell adhesion, replication and differentiation. 85 Thus, Egr-1, like HIF 86 is an inducible proangiogenic gene regulatory factor.
Concluding Remarks
Egr-1 is a master regulator that plays a key role in a variety of cardiovascular pathological processes such as atherosclerosis, intimal thickening following acute vascular injury, ischemia-reperfusion, cardiac hypertrophy, allograft rejection, and angiogenesis. Much of this knowledge has been derived from investigations using Egr-1-null mice or specific molecular suppressors of Egr-1, such as antisense oligonucleotides, decoys, siRNA, DNAzymes, or NABs. Egr-1 dynamically links changes in the local cellular environment with the altered expression of key genes mediating a broad spectrum of vascular pathologies. Egr-1 transcriptional activity involves functionally important interactions with NABs and other regulators, although this knowledge is still relatively limited. The influence of oxidation, phosphorylation, acetylation, and deacetylation on Egr-1 transactivation and the specific disease contexts involved are also not clear. Future studies should address these deficiencies and extend the key pathophysiological roles of Egr-1 beyond rodent models, from where much of our current understanding on Egr-1 is largely derived, to larger animal systems. This will help direct which of the panoply of cardiovascular conditions possibly regulated by Egr-1 in humans could be targeted with Egr-1-specific strategies as primary or adjunctive therapies.
